COVID-19: FabiFlu replaces anti-diabetic drug to become top-selling pharma brand in India
COVID-19: FabiFlu replaces anti-diabetic drug to become top-selling pharma brand in India Fabiflu mops up Rs 762 cr sales in the last 12 months, higher than the anti-diabetic drug, Glycomet-GP sales of Rs 564 crore. (Image Source: ANI) Updated: May 11, 2021, 12:58 PM IST As India reels under a second and more deadly wave of the COVID-19 pandemic, the COVID drug FabiFlu sales witness a jump of 600% in the month of April. Glenmark's FabiFlu, the generic version of Japanese anti-influenza drug Favipiravir is now the top-selling brand in the pharma retail market o...
Source: dnaindia.com